Example sentences (4)
Aridis Pharmaceuticals currently has an average rating of Buy and a consensus price target of $14.
Maxim Group assumed coverage on Aridis Pharmaceuticals in a report on Friday, April 10th.
Aridis Pharmaceuticals (NASDAQ:ARDS) last announced its quarterly earnings data on Monday, August 12th.
Finally, Northland Securities set a $22.00 target price on Aridis Pharmaceuticals and gave the company a “buy” rating in a report on Monday, September 30th.